Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study

Autor(es)

Visacri, Marilia Berlofa ; Pincinato, Eder de Carvalho ; Ferrari, Graziele Baldan ; Franca Quintanilha, Julia Coelho ; Mazzola, Priscila Gava ; Passos Lima, Carmen Silvia ; Moriel, Patricia

• Tipo de documento: Artigo Científico
• Fonte: DARU-JOURNAL OF PHARMACEUTICAL SCIENCES; v. 25, p. 9-pg., 2017-04-24.

Resumo

Background: Cisplatin is a high-potency anticancer agent; however, it causes significant adverse drug reactions (ADRs). Potential pharmacokinetic markers must be studied to predict or prevent cisplatin-induced ADRs and achieve better prognosis. This study was designed to investigate the relationship between ADRs and kinetics of cisplatin excretion in the urine of patients undergoing high-dose cisplatin chemotherapy and radiotherapy for head and neck cancer. Methods: Outpatients with head and neck cancer received a first cycle of high-dose cisplatin chemotherapy (80-100 mg/m(2)) concurrent to radiotherapy. ADRs (haematological, renal, and gastrointestinal reactions) were classified based on severity by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 4, grade 0-4). The kinetics of cisplatin excretion in urine was evaluated by high-performance liquid chromatography over three time periods: 0-12, 12-24, and 24-48 h after the administration of cisplatin. Spearman Correlation test and regression analysis were performed to assess the relationship between ADRs and cisplatin excretion in the urine. Results: In total, 59 patients with a mean age of 55.6 +/- 9.4 years were analysed; most patients were male (86.4%), white (79.7%), and with pharyngeal tumours in advanced stages (66.1%). The most frequently observed ADRs were anaemia (81.4%), lymphopenia (78%), and nausea (64.4%); mostly grades 1 and 2 of toxicity. The mean cisplatin excretion was 70.3 +/- 64.4, 7.3 +/- 6.3, and 5 +/- 4 mu g/mg creatinine at 0-12, 12-24, and 24-48 h, respectively. Statistical analysis showed that the amount of cisplatin excreted did not influence the severity of ADRs. Conclusions: The most frequent ADRs were anaemia, lymphopenia, and nausea. Grades 1 and 2 were the severities for most ADRs. The period over which the highest cisplatin excretion observed was 0-12 h after chemotherapy, and cisplatin excretion could not predict toxicity. (AU)

• Processo FAPESP: 12/01807-2 - Farmacogenética da cisplatina em portadores de carcinoma de células escamosas de cabeça e pescoço
• Beneficiário: Carmen Silvia Passos Lima
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/18294-3 - Avaliação do uso da N-acetilcisteína na atenuação de toxicidades causadas por estresse oxidativo em pacientes com câncer de cabeça e pescoço em tratamento com cisplatina
• Beneficiário: Patricia Moriel
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/04744-7 - Avaliação do uso da N-acetilcisteína na atenuação de toxicidades causadas por estresse oxidativo em pacientes com câncer de cabeça e pescoço em tratamento com cisplatina
• Beneficiário: Marília Berlofa Visacri
• Modalidade de apoio: Bolsas no Brasil - Doutorado